Adherence to lipid-lowering therapy and reaching treatment goals in youth seen in a preventive cardiology clinic
- PMID: 36543634
- PMCID: PMC9870927
- DOI: 10.1016/j.sapharm.2022.12.004
Adherence to lipid-lowering therapy and reaching treatment goals in youth seen in a preventive cardiology clinic
Abstract
Introduction: The efficacy of lipid-lowering therapy in reducing cardiovascular disease in adults is well-established. Unfortunately, it is also well-established that adults have inadequate adherence to lipid-lowering therapy, which is associated with increased costs and mortality. However, the adherence patterns of youth prescribed lipid-lowering therapy is not well-described.
Methods: We analyzed data that was prospectively collected from patients <27 years-old who were referred to a large regional preventive cardiology clinic from 2010 to 2017. Adherence to lipid-lowering therapy was self-reported at the patient's most recent clinic visit and categorized as either adequate adherence (≥80%) or inadequate adherence (<80%). We compared adherence rates by demographic factors, class of lipid-lowering therapy, length of time on lipid-lowering therapy, family history, lipid parameters, and laboratory measures of adverse effects.
Results: In our cohort, we had 318 patients prescribed a lipid-lowering medication over a seven-year period. Of those, 235 (75%) had adequate adherence. Those with adequate adherence had an improved LDL-C (123 mg/dL [standard deviation (SD) 32.3] vs. 167 mg/dL [SD 50.4], p < 0.05), total cholesterol (198 mg/dL [49.5] vs. 239 mg/dL [SD 53.2]), and non-HDL-C (148 mg/dL [SD 38.7] vs. 193 mg/dL [SD 43.9]). In addition, patients with adequate adherence were more likely to reach goal LDL-C of <130 mg/dL than those with inadequate adherence (130 vs. 25, p < 0.01). The relationship between LDL-C and adherence remained statistically significant after controlling for age, gender, and the length of time on therapy (β = -0.66, p < 0.01). Adherence level did not differ by gender, class of lipid-lowering therapy, length of time on lipid-lowering therapy, or presence of a family history of an atherosclerotic event. The findings were similar when we only analyzed those prescribed a statin.
Conclusions: Self-reported adherence to lipid-lowering therapy in youth is excellent and was associated with achieving goal LDL-C goals. Obtaining adherence data from patients may help more patients reach LDL-C goals.
Copyright © 2022 Elsevier Inc. All rights reserved.
Conflict of interest statement
Similar articles
-
DemographIc Assessment and EValuation of DEgree of Lipid Control in High Risk Indian DySlipidemia PatiEnts (DIVERSE Study).J Assoc Physicians India. 2016 Apr;64(4):38-46. J Assoc Physicians India. 2016. PMID: 27734640
-
Vascular Quality of Care Assessment: Clinicians' Adherence to Lipid-Lowering Therapy for Patients with Atherosclerotic Cardiovascular Disease.Ann Vasc Surg. 2020 Nov;69:197-205. doi: 10.1016/j.avsg.2020.06.003. Epub 2020 Jun 15. Ann Vasc Surg. 2020. PMID: 32554202
-
Sex specific analysis of patients with and without reported statin intolerance referred to a specialized outpatient lipid clinic.Biol Sex Differ. 2024 Sep 2;15(1):67. doi: 10.1186/s13293-024-00642-y. Biol Sex Differ. 2024. PMID: 39223591 Free PMC article.
-
Lowering Targeted Atherogenic Lipoprotein Cholesterol Goals for Patients at "Extreme" ASCVD Risk.Curr Diab Rep. 2019 Nov 21;19(12):146. doi: 10.1007/s11892-019-1246-y. Curr Diab Rep. 2019. PMID: 31754844 Review.
-
2017 Taiwan lipid guidelines for high risk patients.J Formos Med Assoc. 2017 Apr;116(4):217-248. doi: 10.1016/j.jfma.2016.11.013. Epub 2017 Feb 24. J Formos Med Assoc. 2017. PMID: 28242176 Review.
Cited by
-
Evaluating the Efficacy of a Pre-Established Lipid-Lowering Algorithm in Managing Hypercholesterolemia in Patients at Very High Cardiovascular Risk.J Pers Med. 2024 Oct 9;14(10):1044. doi: 10.3390/jpm14101044. J Pers Med. 2024. PMID: 39452551 Free PMC article.
-
Midterm Follow-Up of Familial Hypercholesterolemia from a Cross-Sectional School-Based Cholesterol Screening Program.J Pediatr Clin Pract. 2024 Mar 16;11:200109. doi: 10.1016/j.jpedcp.2024.200109. eCollection 2024 Mar. J Pediatr Clin Pract. 2024. PMID: 39949566 Free PMC article.
References
-
- Avorn M J, Lacour A, Bohn RL, et al. Persistence of Use of Lipid-Lowering Medications: A Cross-National Study. JAMA. 1998;279(18). - PubMed
-
- Braamskamp MJAM. Effect of Rosuvastatin on Carotid Intima-Media Thickness in Children With Heterozygous Familial Hypercholesterolemia: The CHARON Study (Hypercholesterolemia in Children and Adolescents Taking Rosuvastatin Open Label). Circulation. 2017;136(4):359–366. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical